Tildrakizumab
Based on 1 Customer Validation
Tildrakizumab (SCH 900222) is a humanized anti-IL-23 (p19 subunit) monoclonal antibody. IL-23 is a critical cytokine to maintain the Th17 cell phenotype. Tildrakizumab has high-affinity for single-chain IL-23 (Kd: 136 pM). Tildrakizumab is effective against moderate to severe plaque psoriasis.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.46%
- No. CAS: 1326244-10-3
- Peso molecular:144.44 kDa
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-P99248
RisankizumabIL-23 IgG Monoclonal Antibody -
HY-P9931
GuselkumabIL-23 Neutralizing Antibody -
HY-P9909
Ustekinumab -
HY-P99737
MirikizumabIL-23 Antibody -
HY-P99486
BriakinumabAnti-IL-12/23p40 Antibody -
HY-P99025
LebrikizumabIL-13 Inhibitor -
HY-P99396
Spesolimab (WT IgG1)Anti-IL-36R Antibody -
HY-P99053
TralokinumabIL-13 Inhibitor -
HY-P99244
FezakinumabIL-22 Antibody -
HY-P9927
SecukinumabIL-17A Antagonist -
HY-108810
CanakinumabAnti-IL-1β Monoclonal Antibody -
HY-P9956
SiltuximabAnti-IL-6 mAb
Actividad biológica
Descripciòn
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
IL-23A
In Vitro
Tildrakizumab inhibits IL-23-induced STAT3 signaling in HeLa cells expressed the human IL-23Rα and IL-12Rβ1 receptors, with an IC50 of 23 pM[2].
Tildrakizumab reduces IL-23’s affinity for IL-23Rα through a negative allosteric modulation[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Ensayo clínico
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Aplicación
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Human IL-23 alpha Protein can bind Tildrakizumab. The ED50 for this effect is 95.45 ng/mL.
Chemical Information
-
No. CAS 1326244-10-3
-
Appearance Liquid
-
Peso molecular 144.44 kDa
-
Color Colorless to light yellow
-
SMILES
[Tildrakizumab]
-
Synonyms
SCH 900222; MK 3222; Anti-Human IL23 Recombinant Antibody
-
Envío
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
-
Ficha de datos (272 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Referencias
[1]. Papp K, et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015 Oct;173(4):930-9. [Content Brief]
[2]. Zhou L, et al. A non-clinical comparative study of IL-23 antibodies in psoriasis. MAbs. 2021 Jan-Dec;13(1):1964420. [Content Brief]
[3]. Santostefano M, et al. Nonclinical safety of tildrakizumab, a humanized anti-IL-23p19 monoclonal antibody, in nonhuman primates. Regul Toxicol Pharmacol. 2019 Nov;108:104476. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Tildrakizumab Related Classifications
HY-P99256 Related Classifications
Powered by Bioz